Catalyst overview
Research summary
This catalyst tracks a Phase 1/2 data readout for AL001 in Healthy Subjects (Baseline Study). The expected timing is based on the latest available company guidance and may change.
Collab w/ MGH. 5/29/25- Dosed first patient. Serve as baseline study. 11/19/25– Completed trial; topline data Q1 2026. 03/16/26:- 'Lithium In Brain' healthy-subjects topline data expected by end of March 2026. 03/26/26:- Ph2 Lithium In Brain healthy-subjects topline positive; bioequivalence met; higher brain lithium vs lithium carbonate. 04/07/26:- Preliminary Phase 2 MRS pharmacodynamic results suggest improved tolerability versus lithium carbonate. 08/18/26:- Phase 1/2A pharmacokinetic lithium imaging results present at ISMRM on September 29, 2026. 08/20/26:- Neuroscience 2026 poster on Nov 18, 2026 reports 7T resting-state fMRI results.
Verification
Confirm timing and program details against the company announcement or filing.